After each Alzheimer’s drug failure, the inevitable question is always asked what are we doing wrong. Anavex (AVXL), Glovia, and India Globalization Capital (IGC) are three companies that may have the correct answer.
Each company’s drug candidate acts as an antioxidant and this is likely the key to treating Alzheimer’s disease. Following is compelling evidence that oxidation and nitration are the key factors behind the onset and progression of Alzheimer’s disease:
The increase in oxidative stress and the decrease in the brain’s main antioxidant glutathione exactly parallels the onset and progression